KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Other Operating Expenses (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Operating Expenses data on record, last reported at $43.4 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 869.23% year-over-year to $43.4 million; the TTM value through Sep 2025 reached -$196.5 million, down 4014.64%, while the annual FY2024 figure was -$160.3 million, 202.24% down from the prior year.
  • Other Operating Expenses reached $43.4 million in Q3 2025 per NKTR's latest filing, up from -$42.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $103.2 million in Q1 2023 and bottomed at -$197.3 million in Q4 2024.
  • Average Other Operating Expenses over 5 years is $5.2 million, with a median of $7.7 million recorded in 2021.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 1840.85% in 2023, then crashed 2491.74% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $6.2 million in 2021, then surged by 287.39% to $23.9 million in 2022, then tumbled by 65.45% to $8.2 million in 2023, then plummeted by 2491.74% to -$197.3 million in 2024, then skyrocketed by 122.02% to $43.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $43.4 million in Q3 2025, -$42.8 million in Q2 2025, and $169000.0 in Q1 2025.